Loading clinical trials...
Loading clinical trials...
A Phase I Dose Escalation Trial of Once Daily Oral Treatment Using Afatinib (BIBW2992) Plus Gemcitabine or Docetaxel in Patients With Relapsed or Refractory Solid Tumors.
Conditions
Interventions
Afatinib
Afatinib
+2 more
Locations
3
France
1200.93.33002 Boehringer Ingelheim Investigational Site
Dijon, France
1200.93.33001 Boehringer Ingelheim Investigational Site
Saint-Herblain, France
1200.93.33003 Boehringer Ingelheim Investigational Site
Toulouse, France
Start Date
November 1, 2010
Primary Completion Date
April 1, 2015
Completion Date
April 1, 2015
Last Updated
May 30, 2016
NCT00026884
NCT07169851
NCT07159659
NCT07213804
NCT07191730
NCT06662786
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions